News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Amgen stock has delivered strong gains over the past five years, yet the current …
Sharemaestro market context Trend signal active 52 weeks +66.3%Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is …
Sharemaestro market context Trend signal active 52 weeks +66.3%Amgen's stock has shown strong returns over the past five years, but recent valuation checks present a mixed picture. While a Discounted Cash Flow (DCF) analysis suggests meaningful upside, estimating an intrinsic value of $668 per share against a market price of $417.84, the …
Amgen SVP Rachna Khosla sold 2,000 shares of AMGN stock for $825,140 on August 11th, reducing her direct holdings by 23.8%. Two days later, she sold an additional 1,252 shares for approximately $521,370. This comes as Amgen reported strong quarterly earnings and revenue, exceeding …
Amgen insider Rachna Khosla has filed a Form 144, indicating an intention to sell up to 516,775 shares of Amgen common stock around August 13, 2026, through Fidelity Brokerage Services LLC on NASDAQ. These shares were acquired via a stock option exercise on August …
Rachna Khosla, Senior Vice President of Business Development at Amgen Inc. (NASDAQ:AMGN), sold approximately $1.35 million worth of company stock through two transactions in mid-August. These sales involved both direct stock sales and shares acquired through the exercise of non-qualified stock options. Following these …
Daiwa Securities has increased its price target for Amgen (AMGN) from $390 to $430, while maintaining an "Outperform" rating on the stock. This adjustment reflects a positive outlook from the firm regarding the biotechnology group. The article also lists other recent analyst adjustments for …
Barclays has adjusted its price target for Amgen (AMGN) to $380, an increase from the previous $360, while maintaining an Equalweight rating on the stock. This update reflects Barclays' ongoing assessment of the biotechnology company's valuation. The article also notes recent adjustments by other …
Amgen's Q2 Earnings Call: Our Top 5 Analyst Questions Amgen's second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key products like Repatha, EVENITY, and TEZSPIRE for the company's outperformance versus Wall Street estimates. CEO Robert Bradway highlighted that 22 …
Sharemaestro market context Trend signal active 52 weeks +66.3%Amgen (AMGN) is experiencing renewed interest after strong Q2 2026 results and raised full-year guidance, leading to a significant jump in share price. While one valuation model suggests the stock is 15.6% overvalued at $416.18, another Discounted Cash Flow (DCF) model estimates it as …
Amgen recently raised its full-year revenue guidance, typically a positive signal, but its stock has not seen a significant celebratory pop. While the company's current performance is strong with multiple products showing double-digit growth, the market appears to have already factored this in. Investors …
Amgen's stock is trading near a yearly high after reporting strong Q2 2026 results, with EPS of $6.29 beating estimates by $0.67 and revenue reaching $10.05 billion. The company also raised its full-year EPS guidance and announced a quarterly dividend, alongside positive news regarding …
Tema ETFs LLC significantly increased its stake in Amgen Inc. by 14.5% during the second quarter, bringing its total holdings to 26,231 shares valued at approximately $9.5 million. This move comes as Amgen reported strong Q2 earnings, beating analyst estimates with EPS of $6.29 …
G&S Capital LLC has made a new $1.58 million investment in Amgen Inc. by purchasing 4,359 shares in the second quarter. The medical research company recently exceeded quarterly earnings and revenue expectations, reporting $6.29 EPS and $10.05 billion in revenue. Amgen also declared a …
Amgen (NASDAQ: AMGN) announced its plan to open a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global R&D network. This new center aims to integrate experimental science with data and technology to accelerate the discovery and development of innovative medicines. …
Sharemaestro market context Trend signal active 52 weeks +66.3%Handelsbanken Fonder AB increased its stake in Amgen Inc. by 15.7% in the second quarter, now owning 346,596 shares valued at $125.51 million. Several other institutional investors also adjusted their positions in Amgen. The article also provides financial details, recent earnings, dividend information, and …
KMG Fiduciary Partners LLC increased its stake in Amgen Inc. by 38.9% in the second quarter, bringing its total holdings to 9,856 shares valued at $3.57 million. Institutional investors now own 76.5% of Amgen's stock. The company recently beat earnings expectations, reporting $6.29 EPS …
Amgen director Charles M. Holley reported receiving a compensation-related grant of 103.4189 shares of common stock on August 7, 2026. Following this award, he directly holds 12,990.4520 shares, which include Dividend Equivalents, and indirectly holds 1,260.0000 shares through the Holley Family Trust. This transaction …
Amgen director Michael V. Drake was granted 63.8764 shares of common stock as compensation on August 7, 2026. This automatic award, valued at $0.00 per share, increases his direct holdings to 5,876.1633 shares, which includes 377 Dividend Equivalents linked to unvested Restricted Stock Units. …
Guggenheim has increased its price target for Amgen Inc. (NASDAQ:AMGN) to $388 from $343, maintaining a Neutral rating after the company's strong second-quarter 2026 earnings. Amgen surpassed both Guggenheim's and consensus expectations, leading to revised fiscal year 2026 revenue and EPS estimates. Despite the …
Amgen Inc. (AMGN) is a significant player in the healthcare sector with a market capitalization of $221.79 billion. The company boasts a strong financial position, evidenced by its forward P/E ratio of 17.03, a remarkable return on equity of 91.47%, and robust free cash …
HSBC has increased its target price for Amgen Inc. shares to $445, up from the previous $425. This adjustment reflects a positive outlook from the banking giant on the pharmaceutical company's stock.
Erste Group Bank has lowered its FY2027 EPS estimate for Amgen to $23.50 from $23.58, while maintaining a "Hold" rating on the stock. This revised estimate still remains above the current full-year consensus of $22.78. Amgen reported strong Q2 results, with EPS of $6.29 …
Amgen, a leader in biotechnology, is experiencing broad-based growth despite biosimilar competition for Prolia, leading Morningstar to maintain its fair value assessment. The company's flagship drugs include Epogen, Aranesp, Neupogen, Neulasta, Enbrel, Otezla, and its first cancer therapeutic, Vectibix. The current stock price is …
Avity Investment Management Inc. significantly increased its stake in Amgen Inc. by 5.3% in the second quarter, bringing its total holdings to 76,186 shares valued at approximately $27.59 million. Amgen recently reported strong second-quarter results, exceeding revenue and EPS expectations, and raised its 2026 …
Cardano Risk Management B.V. has reduced its stake in Amgen Inc. by 5.2%, selling 14,358 shares and retaining 260,359 shares valued at $94.3 million. Amgen reported strong Q2 2026 results, exceeding revenue and EPS expectations, and raised its full-year earnings guidance despite discontinuing an …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Amgen is back in focus after updated valuation work lifted its modeled fair value from US$352.23 to US$371.93 per share, signaling a higher …
Sharemaestro market context Trend signal active 52 weeks +66.3%Amgen Inc.'s average stock price target has been raised to $378.67 by 27 analysts, up from $376.44. This updated target implies a 6% potential downside based on the August 6 closing price. Despite the potential downside, the consensus rating from 35 analysts remains at …
Amgen's stock rose 6.7% after the European Medicines Agency's CHMP supported broader use of its drug Repatha for high-risk atherosclerotic cardiovascular disease patients in Europe. This potential expansion, driven by positive Phase 3 trial data, could significantly increase Repatha's eligible patient base. While strengthening …
Assenagon Asset Management S.A. significantly reduced its stake in Amgen Inc. by 44.5% during the second quarter, now holding 191,247 shares valued at $69.25 million. Despite this, other institutional investors have increased their positions, and analysts have set new price targets, with a consensus …
Amgen's SVP & CCO, Nancy A. Grygiel, sold approximately $1.19 million worth of Amgen stock on August 6, 2026. This transaction was related to the exercise of non-qualified stock options, with the sales primarily covering the exercise price and withholding taxes. Following these transactions, …
Kevin Simpson, founder and CIO of Capital Wealth Planning, has increased his holdings in Amgen. He discussed his rationale for buying more shares at current price levels during an appearance on CNBC's 'Halftime Report.' The article primarily features a video clip of his explanation.
The Czech National Bank increased its stake in Amgen Inc. by 4.8% in the second quarter, acquiring an additional 6,969 shares and bringing its total holdings to 153,622 shares valued at $55.6 million. This comes as Amgen reported strong second-quarter results, exceeding analyst expectations …
PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Amgen Inc. by 12.3% in the second quarter, bringing its total ownership to 108,300 shares valued at approximately $39.2 million. This comes as Amgen reported strong quarterly results, with a 9.5% revenue increase and raised 2026 adjusted EPS …
Pfizer, Merck, and Amgen are expanding their cancer portfolios, leading to increased speculation about smaller oncology companies like Sellas Life Sciences (SLS) and ImmunityBio (IBRX) being potential acquisition targets. Pfizer's Seagen portfolio and Padcev, Merck's sac-TMT, and Amgen's T-cell engagers and Imdelltra are key …
AMGN added 2.4% in the week to 31 July and sits only 3.2% below its 52-week high, with the Trend Signal active but volume confirmation still modest.
Search by ticker symbol or company name and select a result to open its chart.